Delving into the Latest Updates on Torsemide/Spironolactone with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms-

Target

MR x NKCC1 x NKCC2

Action

antagonists, inhibitors

Mechanism

MR antagonists(Mineralocorticoid receptor antagonists), NKCC1 inhibitors(Solute carrier family 12 member 2 inhibitors), NKCC2 inhibitors(Sodium-(potassium)-chloride cotransporter 2 inhibitors)

Therapeutic Areas-

Active Indication-

Inactive Indication-

Originator Organization

Sarfez Pharmaceuticals, Inc.

Active Organization

Sarfez Pharmaceuticals, Inc.

Inactive Organization-

License Organization-

Drug Highest PhasePhase 3

First Approval Date-

Regulation-

Login to view timeline

This study examines the bioavailability and bioequivalence of single dose of a Fixed Dose Combination (FDC) tablet (12 mg Extended-Release Torsemide and 15mg Spironolactone). The goal of this study is to determine PK/PD effects of the FDC, 10 mg Torsemide alone, 25mg Aldactone® (Spironolactone) alone, and 10 mg Torsemide and 25 mg Aldactone® (Spironolactone) taken together in healthy subjects.

Start Date01 Jul 2025

Sponsor / Collaborator

Sarfez Pharmaceuticals, Inc.

NCT07043634

/ CompletedPhase 3

An Open Label, Randomized, Two-period, Two-sequence, Balanced, Single Dose Crossover Study to Evaluate the Effect of Food on the Bioavailability of Extended Release (ER) Torsemide and Spironolactone Fixed Dose Combination (FDC) Tablet in Healthy Adult Human Subjects

This study will examine comparative bioavailability of single dose of a fixed dose combination (FDC) of extended release Torsemide and Spironolactone given with or without food in healthy adult subjects.

Start Date15 Jun 2025

Sponsor / Collaborator

Sarfez Pharmaceuticals, Inc.

NCT07223502

/ WithdrawnPhase 3

A Randomized, Parallel, Two Arm Study Comparing the Net Clinical Benefit of Finerenone Versus a Fixed Dose Combination of Extended-Release Torsemide and Spironolactone in Patients With Hypertension and PRoteinuric ChrOnic KidNey Disease

A study Comparing the Clinical Benefit of Finerenone Versus a Fixed-Dose Combination (FDC) of Extended-Release Torsemide and Spironolactone in Patients with Hypertension and Chronic Kidney Disease.

Start Date01 May 2025

Sponsor / Collaborator

Sarfez Pharmaceuticals, Inc.

100 Clinical Results associated with Torsemide/Spironolactone

Login to view more data

100 Translational Medicine associated with Torsemide/Spironolactone

Login to view more data

100 Patents (Medical) associated with Torsemide/Spironolactone

Login to view more data

100 Deals associated with Torsemide/Spironolactone

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D00382	-	-	-

R&D Status

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


AASLD2025	Not Applicable	-	103	Furosemide-Spironolactone (FS)	gvtgffbuwt(mzvgrhdgnh) = The occurrence of muscle cramps (24.5% vs 20.3%, p=0.79), hyponatremia (55.1% vs 53.7%, p=1.00), hypokalemia (10.2% vs 11.1%, p=1.00), hypomagnesemia (16.3% vs 20.3%, p=0.78), incidence of AKI (22.4% vs 22.2%, p=1.00) were similar in both groups. cqgflckdoz (zlmvxhhjwa ) View more	Positive	07 Nov 2025
				Torsemide-Spironolactone (TS)